Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa

Malaria Journal

Volumn 2, Issue , 2003, Pages 1-3

  Ochong, Edwin ^a   Nzila, Alexis ^a,b   Kimani, Serah ^a   Kokwaro, Gilbert ^a   Mutabingwa, Theonest ^c,d   Watkins, William ^b   Marsh, Kevin ^a,e  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FANSIDAR; ISOLEUCINE; LEUCINE;

AFRICA; ALLELE; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; GENE EXPRESSION SYSTEM; HUMAN; INFANT; MALARIA FALCIPARUM; MUTATIONAL ANALYSIS; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 3042595929     PISSN: 14752875     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2875-2-1     Document Type: Article

References (10)

1. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W: Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001, 358:1218-23.
2. Winstanley P: Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health 2001, 6:952-954.
3. Lang T, Greenwood B: The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003, 3: 162-168.
4. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM: Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 2001, 17:582-528.
5. Watkins WM, Mberu EK, Winstanley PA, Plowe CV: The Efficacy of antifolate antimalarial combination in africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997, 13:459-464.
6. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, Alloueche A, Warhurst DC: Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. J Infect Dis 2002, 186:1861-4.
7. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH: Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg 2002, 96:674-6.
8. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM: Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000, 44:991-996.
9. Wichmann O, Jelinek T, Peyerl-Hoffmann G, Muhlberger N, Grobusch MP, Gascon J, Matteelli A, Hatz C, Laferl H, Schulze M, Burchard G, Cunha Sd S, Beran J, McWhinney P, Kollaritsch H, Kern P, Cuadros J, Alifrangis M, Gjorup I: Molecular surveillance of the antifolate-resistant mutation I164L in imported african isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malar J 2003, 2:17.
10. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ: A selective sweep driven by pyrimethamine treatment in South East Asian malaria parasites. Mol Biol Evol 2003, 20:1526-36.